MDGL
Price
$299.51
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
6.68B
37 days until earnings call
PTGX
Price
$55.69
Change
+$0.47 (+0.85%)
Updated
Jun 27 closing price
Capitalization
3.45B
31 days until earnings call
Interact to see
Advertisement

MDGL vs PTGX

Header iconMDGL vs PTGX Comparison
Open Charts MDGL vs PTGXBanner chart's image
Madrigal Pharmaceuticals
Price$299.51
Change-$0.00 (-0.00%)
Volume$369
Capitalization6.68B
Protagonist Therapeutics
Price$55.69
Change+$0.47 (+0.85%)
Volume$1.55M
Capitalization3.45B
MDGL vs PTGX Comparison Chart in %
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. PTGX commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Buy and PTGX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (MDGL: $299.51 vs. PTGX: $55.69)
Brand notoriety: MDGL and PTGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 0% vs. PTGX: 172%
Market capitalization -- MDGL: $6.68B vs. PTGX: $3.45B
MDGL [@Biotechnology] is valued at $6.68B. PTGX’s [@Biotechnology] market capitalization is $3.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 0 FA rating(s) are green whilePTGX’s FA Score has 1 green FA rating(s).

  • MDGL’s FA Score: 0 green, 5 red.
  • PTGX’s FA Score: 1 green, 4 red.
According to our system of comparison, PTGX is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 6 TA indicator(s) are bullish while PTGX’s TA Score has 5 bullish TA indicator(s).

  • MDGL’s TA Score: 6 bullish, 4 bearish.
  • PTGX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than PTGX.

Price Growth

MDGL (@Biotechnology) experienced а +4.82% price change this week, while PTGX (@Biotechnology) price change was +4.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

MDGL is expected to report earnings on Aug 06, 2025.

PTGX is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.68B) has a higher market cap than PTGX($3.45B). PTGX YTD gains are higher at: 44.275 vs. MDGL (-2.936). PTGX has higher annual earnings (EBITDA): 30.1M vs. MDGL (-376.15M). MDGL has more cash in the bank: 843M vs. PTGX (574M). PTGX has less debt than MDGL: PTGX (11.4M) vs MDGL (120M). MDGL has higher revenues than PTGX: MDGL (317M) vs PTGX (208M).
MDGLPTGXMDGL / PTGX
Capitalization6.68B3.45B193%
EBITDA-376.15M30.1M-1,250%
Gain YTD-2.93644.275-7%
P/E RatioN/A71.40-
Revenue317M208M152%
Total Cash843M574M147%
Total Debt120M11.4M1,053%
FUNDAMENTALS RATINGS
MDGL vs PTGX: Fundamental Ratings
MDGL
PTGX
OUTLOOK RATING
1..100
1550
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
80
Overvalued
PROFIT vs RISK RATING
1..100
4244
SMR RATING
1..100
9755
PRICE GROWTH RATING
1..100
5438
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (65) in the Pharmaceuticals Other industry is in the same range as PTGX (80) in the Biotechnology industry. This means that MDGL’s stock grew similarly to PTGX’s over the last 12 months.

MDGL's Profit vs Risk Rating (42) in the Pharmaceuticals Other industry is in the same range as PTGX (44) in the Biotechnology industry. This means that MDGL’s stock grew similarly to PTGX’s over the last 12 months.

PTGX's SMR Rating (55) in the Biotechnology industry is somewhat better than the same rating for MDGL (97) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew somewhat faster than MDGL’s over the last 12 months.

PTGX's Price Growth Rating (38) in the Biotechnology industry is in the same range as MDGL (54) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew similarly to MDGL’s over the last 12 months.

PTGX's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew significantly faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLPTGX
RSI
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
64%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
78%
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 13 days ago
81%
Bearish Trend 10 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
73%
Aroon
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RNGFX68.670.30
+0.44%
American Funds New Economy R5
HIADX24.650.10
+0.41%
Hartford Dividend and Growth HLS IA
TSPTX5.900.02
+0.34%
Transamerica Small Cap Growth I3
PIBQX18.320.05
+0.27%
PGIM Balanced R6
MSGRX12.79N/A
N/A
Meridian Small Cap Growth Institutional

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with NAGE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then NAGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
N/A
NAGE - MDGL
44%
Loosely correlated
+2.89%
VIR - MDGL
39%
Loosely correlated
-2.64%
RVMD - MDGL
38%
Loosely correlated
-1.52%
AKRO - MDGL
37%
Loosely correlated
-0.16%
KRYS - MDGL
36%
Loosely correlated
-2.60%
More

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been closely correlated with BIESF. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if PTGX jumps, then BIESF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
+0.86%
BIESF - PTGX
67%
Closely correlated
N/A
MLYS - PTGX
51%
Loosely correlated
-2.07%
TRVI - PTGX
44%
Loosely correlated
-0.71%
FULC - PTGX
38%
Loosely correlated
-3.79%
MDGL - PTGX
35%
Loosely correlated
N/A
More